Ivonescimab vs FOLFOX for advanced bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug, ivonescimab, compared to standard chemotherapy (FOLFOX) for people with advanced bile duct cancer that has progressed after initial treatment. It aims to see if ivonescimab can help control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a type of bile duct cancer that has spread or cannot be removed by surgery.
- You have already been screened for the SAFIR-ABC10 trial and your cancer has gotten worse after your first chemotherapy (cisplatin/gemcitabine).
- You are generally well enough to do all your daily activities (ECOG score 0 or 1).
- Any bile duct blockage has been treated, and you have no active infection.
- Your blood tests show good bone marrow, liver, and kidney function, and you have no uncontrolled high blood pressure or recent major bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs (ivonescimab, liposomal irinotecan, and 5-FU/LV) in people with bile duct or gallbladder cancer that hasn't been treated yet. The goal is to shrink the tumor enough so that it can be removed with surgery.
This trial tests a new combination of a drug that helps your immune system fight cancer, called sintilimab, along with chemotherapy. It is for people who have bile duct cancer or gallbladder cancer that has spread to other parts of the body and have not had treatment for this stage yet. The goal is to see if this combination helps shrink tumors or stops them from growing.
This trial tests a combination of two chemotherapy drugs and an immunotherapy drug, followed by targeted radiation, in people with bile duct or gallbladder cancer that cannot be removed with surgery. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests the drug Ivosidenib for people with advanced bile duct cancer that has a specific genetic change called an IDH1 mutation. It may be an option if you haven't had chemotherapy yet or if your cancer returned more than 6 months after surgery.
This Phase 3 trial matches people with advanced bile duct cancer or gallbladder cancer to a specific targeted medicine based on their tumor’s lab results. It aims to improve disease control by using the right drug for the specific changes found in the cancer.
This study tests a new drug called ivonescimab plus standard chemotherapy, compared to the usual chemo and immunotherapy (pembrolizumab or durvalumab), for people with advanced bile duct or gallbladder cancer. The goal is to see if the new combination helps patients live longer without the cancer growing.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.